About us
Management

About us


The GDB management team consists of world-leading scientists with decades of experience in pioneering the oral delivery of large molecules.Our formulation technology is built on a deep understanding of physical chemistry, membrane science, and gastrointestinal physiology across animals and humans. We apply this expertise with a strong focus on R&D practicality, ensuring the use of safe excipients and maintaining close interactions with regulatory agencies to seek guidance and establish efficient, well-defined R&D pathways.

For these unique oral formulations, the quantitative and accurate translation of formulation and DMPK data between animals and humans is especially critical. In this field, the GDB team brings three decades of academic research at leading universities, over ten years of DMPK and clinical pharmacology R&D experience at major pharmaceutical companies, and four years of dedicated formulation development for the oral delivery of large molecules. This includes conducting hundreds of large-animal PK studies internally at GDB.

 

ABUIABACGAAgubLZuwYoo_TtkQEwvgo4-g0

Huadong Tang, Ph.D.

Founder, Interim Chief Executive Officer

Huadong founded GDB in 2017 and led the Company as the CEO so far. Huadong is a PK/PD expert, who earned his Ph.D. in Pharmaceutical Sciences from the University of Arizona. Huadong is the Inventor of several important models in predicting human pharmacokinetics, which are widely recognized and used in the pharmaceutical industry and academic field. He has worked over 10 years in big pharma (Wyeth, Schering-Plough/Merck, BMS) as DMPK/clinical lead for multiple discovery and clinical development teams in diabetes, oncology, neuroscienceand infectious disease. Huadong founded Shenox Pharmaceuticals, dedicated to developing the transdermal delivery of ketamine for treatment of major depressive disorders. He led the IND/regulatory affairs and clinical studies of the ketamine program.


ABUIABACGAAgsrPZuwYosPXDRTDAAjjgAw

Michael Mayersohn, Ph.D.

Chief Strategy Officer

Michael earned his Ph.D. in Pharmaceutical Sciences at SUNY Buffalo. Michael was a professor at the University of Arizona for 40 years, and the Strategy Officer of GDB from 2017. He was a fellow of the American Association of Pharmaceutical Scientists and a fellow of American Association of Clinical Pharmacology, and the former advisor to PharmaceuticalSciences of FDA and USP Pharmaceutical Sciences. Michael is a highly sought expert in PK/formulation as a witness for IP litigations for numerous marketed drugs with a total value over 10 billion USD.


ABUIABACGAAgyLLZuwYovrDlOTDuBTiaCA


Wenfei Liang

President of China district

Wenfei obtained his bachelor and master degrees from School of Pharmacy, Peking University. He worked for BaiyunshanPharmaceutical as a lead formulation scientist. He joined GDB in 2018, led the development of the MO-PION technology platform and took the leadership of development of GDB in China. Wenfei is a formulation expert with extensive experience in GLP/GMP management experience.


ABUIABACGAAgvYPzvAYozfi32gEwrAI4rAI

A leader in oral technology

Chief Executive Officer (to be effective on Newco)